Rights and permissions
About this article
Cite this article
IRIS: imatinib mesylate superior in first-line treatment of CML. Inpharma Wkly. 1349, 11–12 (2002). https://doi.org/10.2165/00128413-200213490-00025
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128413-200213490-00025